Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of S-Rolipram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 12/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | VEGFA | P15692 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Rolipram SCHEMBL5321568 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL29360376 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL29598924 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL27930 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL576805 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL3719855 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3544304 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL28973411 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL15208132 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3554826 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025095107-A1 | METHOD FOR PRODUCING PLATEABLE HEPATOCYTES AND APPLICATION THEREOF | 公立大学法人名古屋市立大学 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025018366-A1 | METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELLS | 公立大学法人名古屋市立大学 | 2025-01-23 | — | — | WO | disclosed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240271088-A1 | METHOD FOR MAINTAINING AND AMPLIFYING HUMAN PRIMORDIAL GERM CELLS / HUMAN PRIMORDIAL GERM CELL-LIKE CELLS | KYOTO UNIVERSITY (JP) | 2024-08-15 | — | — | US | disclosed |
| CN-118078811-A | Application of chiral beta-catechol substituted cyclopentanamide compound | 天津科技大学 | 2024-05-28 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4202041-A1 | METHOD FOR MAINTAINING AND AMPLIFYING HUMAN PRIMORDIAL GERM CELLS / HUMAN PRIMORDIAL GERM CELL-LIKE CELLS | Kyoto University (JP) | 2023-06-28 | — | — | EP | disclosed |
| CN-116323917-A | Method for maintaining and expanding human primordial germ cells/human primordial germ cell-like cells | 国立大学法人京都大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230133409-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2023-05-04 | — | — | US | disclosed |
| WO-2023074648-A1 | METHOD FOR PRODUCING INTESTINAL ENDOCRINE CELLS, PLURIPOTENT STEM CELL-DERIVED INTESTINAL ENDOCRINE CELLS, MEDIUM OR MEDIUM KIT, AND USE OF THE SAME | 富士フイルム株式会社 | 2023-05-04 | — | — | WO | disclosed |
| EP-4125873-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Hadasit Medical Research Services&Development Ltd. (IL) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022168908-A1 | PRODUCTION METHOD FOR INTESTINAL TRACT CELLS DERIVED FROM PLURIPOTENT STEM CELLS AND HAVING CRYPT-VILLUS-LIKE STRUCTURES, AND USE THEREOF | 公立大学法人名古屋市立大学 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022166796-A1 | PYRIMIDINE OR PYRIDINE AND HETEROCYCLIC ADENOSINE RECEPTOR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022156727-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | 浙江养生堂天然药物研究所有限公司 | 2022-07-28 | — | — | WO | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2022039279-A1 | METHOD FOR MAINTAINING AND AMPLIFYING HUMAN PRIMORDIAL GERM CELLS / HUMAN PRIMORDIAL GERM CELL-LIKE CELLS | 国立大学法人京都大学 | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | PDE4A 1149/4885PDE4B 1906/4885PDE4C 2311/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | PDE4A 4798/4885PDE4B 4588/4885PDE4C 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.